Answers are grounded in this paper and cite their sources.
Invasive fungal infections, although relatively rare, are life-threatening diseases in premature infants and immunocompromised children. While many advances have been made in antifungal therapeutics in the last two decades, knowledge of the pharmacokinetics and pharmacodynamics of antifungal agents for infants and children remains incomplete. This review summarizes the pharmacology and clinical utility of currently available antifungal agents and discusses the opportunities and challenges for future research.
No takes yet. Share an insight, caveat, or question.
Lestner et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: